SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

Conduent Incorporated

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

(CUSIP Number)

DD Revocable Trust
Douglas R. Deason, 3953 Maple Avenue, Suite 150
Dallas, TX, 75205
214-378-3600

Richard M. Brand
White & Case LLP, 1221 Avenue of the Americas
New York, NY, 10020
212-819-8200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/24/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person DD REVOCABLE TRUST	
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)	
3	SEC use only	
4	Source of funds (See Instructions) OO	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 0.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 0.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 0.00 %	
14	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: Note to row 11: The DD Revocable Trust (the "Trust") holds 4,077,528 shares of Common Stock of record and 5,393,256 shares of Common Stock issuable upon the conversion of 120,000 shares of the Issuer's Series A Preferred Stock, par value $0.01 (the "Series A Preferred Stock"), representing an aggregate of 9,470,784 shares of Common Stock. Douglas R. Deason, as trustee of the Trust (the "Trustee"), exercises sole voting and dispositive power over the securities held by the Trust. Such shares are included in the beneficial ownership reported by the Trustee and are not separately reported as beneficially owned by the Trust. Note to row 13: The 9,470,784 shares of Common Stock represented by the Trust's holdings, including 5,393,256 shares issuable upon conversion of its Series A Preferred Stock, represent approximately 5.88% of the Common Stock, based on 155,681,722 shares of Common Stock stated by the Issuer as being outstanding as of October 31, 2026, in its Form 10-Q, filed with the United States Securities and Exchange Commission (the "SEC") on November 5, 2026 (the "2026 Q3 10-Q"), plus those 5,393,256 conversion shares. This percentage relates to the securities held by the Trust over which the Trustee exercises sole voting and dispositive power, not to separate beneficial ownership by the Trust.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person

	DOUGLAS R. DEASON	
	Check the appropriate box if a member of a Group (See Instructions)	
2	☐ (a) ☑ (b)	
3	SEC use only	
	Source of funds (See Instructions)	
4	OO	
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
5	☐	
	Citizenship or place of organization	
6	UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	Sole Voting Power 7 12,321,307.00	
	Shared Voting Power 8 0.00	
	Sole Dispositive Power 9 12,321,307.00	
	Shared Dispositive Power 10 0.00	
	Aggregate amount beneficially owned by each reporting person	
11	12,321,307.00	
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
12	☐	
	Percent of class represented by amount in Row (11)	
13	7.65 %	
	Type of Reporting Person (See Instructions)	
14	IN	

Comment for Type of Reporting Person: Note to rows 7, 9, 11 and 13: Includes 5,393,256 shares of Common Stock issuable upon the conversion of 120,000 shares of Series A Preferred Stock. Of the shares of Common Stock reported, 2,850,523 shares are held by a foundation controlled by the Trustee and certain exempt and non-exempt trusts. Note to row 13: Rounded up to the nearest hundredth of a percent and based on the 155,681,722 shares of Common Stock stated by the Issuer as being outstanding as of October 31, 2026, in the 2026 Q3 10-Q, plus the 5,393,256 shares of Common Stock issuable upon conversion of the Trust's Series A Preferred Stock. Of the shares of Common Stock reported, 2,850,523 shares are held by a foundation controlled by the Trustee and certain exempt and non-exempt trusts.

SCHEDULE 13D

Item 1.	Security and Issuer
	Title of Class of Securities:
(a)	Common Stock, $0.01 par value
	Name of Issuer:
(b)	Conduent Incorporated
	Address of Issuer's Principal Executive Offices:
(c)	100 Campus Drive, Suite 200, Florham Park, NEW JERSEY , 07932.

Item 1 Comment: Explanatory Note: This Amendment No. 4 to Schedule 13D (this "Amendment No. 4") amends and supplements, to the extent set forth herein, the Schedule 13D originally filed by Darwin Deason ("Deason") on December 19, 2018, as

amended by Amendment No. 1 filed by Deason on February 16, 2021, Amendment No. 2 filed by Deason on June 14, 2024 and Amendment No. 3 filed by the DD Revocable Trust, following the passing of Deason, on February 13, 2026 (collectively, as so amended, the "Schedule 13D") relating to the Common Stock of the Issuer. Capitalized terms used in this Amendment No. 4 but not otherwise defined herein shall have the respective meanings ascribed to them in the Schedule 13D.

Item 2. Identity and Background

(a) Item 2(a) of the Schedule 13D is hereby amended and restated in its entirety as follows: "This Amendment No. 4 is filed jointly by the Trust and the Trustee, in his capacity as trustee of the Trust (the Trustee, together with the Trust, the "Reporting Persons"). Following the passing of Darwin Deason, the Trust became irrevocable by operation of law. The Trust is the successor in interest with respect to the shares of Common Stock previously reported as beneficially owned by Darwin Deason and is included as a Reporting Person in that capacity. The Trustee has sole voting and dispositive power over the shares held by the Trust and is the sole beneficial owner of such shares for purposes of this Schedule 13D. The Trust does not separately beneficially own such shares."

(b) Item 2(b) of the Schedule 13D is hereby amended and restated in its entirety as follows: "The principal business address of the Reporting Persons is Deason Capital Services, LLC, 3953 Maple Ave., Suite 150, Dallas, Texas 75219."

(c) The last sentence of the Schedule 13D is hereby deleted in its entirety.

(d) Item 2(d) of the Schedule 13D is hereby amended and restated in its entirety as follows: "During the last five years, neither of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors)."

(e) Item 2(e) of the Schedule 13D is hereby amended and restated in its entirety as follows: "During the last five years, neither of the Reporting Persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws."

(f) The last sentence of Item 2(f) of the Schedule 13D is hereby amended and restated in its entirety as follows: "The Trustee is a citizen of the United States."

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby supplemented by adding the following paragraph: "On November 23, 2026, the Trust purchased an additional 1,000 shares of Common Stock at a price of $0.914 per share, for an aggregate purchase price of $914, excluding any commissions or other transaction costs. The funds used for this purchase were derived from the Trust's available cash. The Trustee, in his capacity as trustee of the Trust, has sole voting and dispositive power over the securities held by the Trust."

Item 4. Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows: "The shares of Common Stock previously reported as beneficially owned by Deason were acquired pursuant to the Spin-Off, and the shares of Series A Preferred Stock previously reported as beneficially owned by Deason were acquired pursuant to the Exchange Agreement. On December 18, 2018, Deason and the Issuer entered into an agreement (the "Agreement"). A copy of the Agreement is incorporated herein by reference as Exhibit 99.1. On June 10, 2024, the Issuer announced that it had consummated a transaction with Carl Icahn and his affiliates pursuant to which the Issuer purchased all of the shares of Common Stock owned by Mr. Icahn and his affiliates (the "Repurchase Transaction"). On December 2, 2025, Deason passed away. Pursuant to the terms of the Last Will and Testament of Deason (the "Will"), upon completion of the probate process with respect to Deason's estate and in accordance with applicable law, the securities previously reported as beneficially owned by Deason were transferred to the Trust of which Mr. Douglas R. Deason is the Trustee. The Trustee now has sole voting and dispositive power over the securities held by the Trust, as described in Item 2. On November 23, 2026, the Trust purchased an additional 1,000 shares of Common Stock, as described in Items 3 and 5. The Reporting Persons are exploring and evaluating alternatives with respect to the Trust's investment in the Issuer (the "Review"). In connection with the Review, the Reporting Persons may from time to time enter into discussions with members of the Issuer's board of directors (individually or acting as a whole), officers of the Issuer, other stockholders of the Issuer, third parties or any of their representatives regarding the Trust's investment in the Issuer. The Reporting Persons have had, and expect to continue to have, preliminary discussions with representatives of certain third parties, including representatives of Ekpyrosis Liberation Opportunities, LLC and Strait Lane Capital Partners, LLC, regarding the Issuer and potential alternatives with respect to the Trust's investment in the Issuer. Such discussions have included, and future discussions may include, without limitation, the governance, board composition, management, operations, business, assets, performance, capitalization, financial condition, strategic plans and future of the Issuer, as well as other matters related to the Issuer. Except as described herein, the Reporting Persons have not entered into any agreements, contracts, arrangements or understandings with any other party relating to acquiring, holding, voting or disposing of any Securities (as defined below). The Reporting Persons disclaim membership in any group with any of the parties with whom they have had, are having or may have discussions as described above, including Ekpyrosis Liberation Opportunities, LLC and Strait Lane Capital Partners, LLC, and disclaim beneficial ownership of any shares of Common Stock held by any such parties, except for shares otherwise expressly reported herein as beneficially owned by a Reporting Person. The Reporting Persons intend to review the Trust's investment in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the outcome of the discussions referenced above, the Issuer's financial position and strategic direction, actions taken by the Issuer's board of directors, price levels of the shares of Common Stock, other investment opportunities available to the Trust, conditions in the securities and other markets, and general economic and industry conditions, the Reporting Persons

may take such actions with respect to the Trust's investment in the Issuer as they deem appropriate, including, without limitation: (i) nominating one or more individuals for election to the Issuer's board of directors or otherwise seeking to change the composition of the Issuer's board of directors or management; (ii) acquiring additional shares of Common Stock and/or other equity, debt, notes, other securities, or derivatives or other instruments that are based upon or relate to the value of the Common Stock or otherwise relate to the Issuer (collectively, "Securities") in the open market or otherwise; (iii) engaging in a strategic transaction involving the Issuer, either alone or together with one or more other investors, including through a merger, tender offer or other business combination or similar transaction; (iv) disposing of any or all of the Securities held by the Trust in the open market, in privately negotiated transactions or otherwise, including by distribution to beneficiaries of the Trust; (v) engaging in hedging or similar transactions with respect to the Securities; or (vi) otherwise proposing or considering, or changing their intentions with respect to, one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D (whether or not otherwise described above). The Reporting Persons may also take steps to explore and prepare for various plans and actions, and propose transactions, before forming an intention to engage in such plans or actions or proceed with such transactions. Without limiting the foregoing, the Trust requested that the Issuer provide copies of its forms of director questionnaires and other certificates, undertakings or similar agreements with respect to the nomination of candidates for election to the Issuer's board of directors." On February 6, 2026, the appropriate court issued Letters Testamentary appointing the Executors as the personal representatives of the Trust. Consequently, the Executors have acquired shared voting and dispositive power over the Shares held by the Trust. The Trust holds the Shares for investment purposes and for the administration and eventual distribution of the Trust's assets in accordance with the Will. The Executors, in their capacity as fiduciaries of the Trust, will continuously evaluate the Issuer's business, financial condition, and the market for the Shares. Depending on market conditions and other factors, the Trust may acquire additional Shares or dispose of some or all of the Shares in the open market, in privately negotiated transactions, or by distribution to the beneficiaries of the Trust. Except as described in this Item 4, the Executors do not presently have any plans or proposals that relate to or would result in any of the matters set forth in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer

(a) Item 5(a) is hereby amended and restated in its entirety as follows: "As of the date hereof, the Trustee may be deemed to beneficially own, in the aggregate, 12,321,307 shares of Common Stock (the "Subject Shares"), including 5,393,256 shares of Common Stock issuable upon the conversion of 120,000 shares of Series A Preferred Stock. The Subject Shares represent approximately 7.65% of the Issuer's outstanding shares of Common Stock (based upon the 155,681,722 shares of Common Stock stated to be outstanding by the Issuer as of October 31, 2026, as reported by the Issuer in the 2026 Q3 10-Q, plus the 5,393,256 shares of Common Stock issuable upon conversion of the Trust's Series A Preferred Stock). The Trustee has the sole power to vote or direct the vote and to dispose of or to direct the disposition of all of the Subject Shares. Of the Subject Shares, 2,850,523 shares are held by a foundation and certain exempt and non-exempt trusts. The Trustee has sole voting and dispositive power over those shares in his capacity as the president of the foundation and as the trustee of each of the trusts."

(b) Item 5(b) is hereby amended and restated in its entirety as follows: "The response to Item 5(a) is incorporated herein by reference."

(c) The first sentence of Item 5(c) is hereby amended and restated in its entirety as follows: "On November 23, 2026, the Trust acquired 1,000 shares of Common Stock at a price of $0.914 per share. Except as disclosed herein, no transactions in the Common Stock were effected by the Reporting Persons during the past 60 days."

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6 of the Schedule 13D is hereby supplemented as follows: "The responses to Items 1, 2, 3, 4, 5 and 7 are incorporated herein by reference. Other than as reported in the Schedule 13D or described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer."

Item 7. Material to be Filed as Exhibits.

Item 7 of the Schedule 13D is hereby amended and restated in its entirety as follows: "Exhibit 99.1 Agreement, dated December 18, 2018 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on December 19, 2018). Exhibit 99.2 Joint Filing Agreement, dated as of November 24, 2026, by and among the Reporting Persons** **Filed herewith."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DD REVOCABLE TRUST

Signature: /s/ Douglas R. Deason
Name/Title: Douglas R. Deason/Trustee
Date: 11/24/2026

DOUGLAS R. DEASON

Signature: /s/ Douglas R. Deason

Name/Title: Douglas R. Deason
Date: 11/24/2026

Exhibit 99.2

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.01 per share, of Conduent Incorporated, and that this agreement be included as an Exhibit 99.2 to such joint filing. This agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.

IN WITNESS WHEREOF, each of the undersigned hereby executes this agreement as of this 24th day of November, 2026.

DD REVOCABLE TRUST

By /s/ Douglas R. Deason
Douglas R. Deason
Trustee

DOUGLAS R. DEASON
/s/ Douglas R. Deason